Dapeng Sun,Xiaochuan Huo,Zhongrong Miao
Dapeng Sun
Emerging technologies and strategies in epilepsy surgery: toward personalised medicine [0.03%]
癫痫外科的新兴技术及策略——朝向个性化医疗
Ruta Yardi,Dario J Englot,Chengyuan Wu et al.
Ruta Yardi et al.
Epilepsy surgery, the treatment of choice for drug-resistant focal epilepsy, is evolving rapidly. This progress is driven by a growing interest in the network theory of epilepsy, advances in data-driven models, and a focus on personalised t...
Colin G McNamara,John F Cryan
Colin G McNamara
Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies [0.03%]
急性卒中的血管内治疗：不断演变的纳入标准和辅助治疗方法
Martina Glavan,Jia Liu,Gisele Sampaio Silva et al.
Martina Glavan et al.
Endovascular thrombectomy is the standard treatment for ischaemic stroke, a leading cause of disability worldwide. Randomised trials in the past decade have expanded eligibility criteria to include broader patient populations, such as those...
Eng-King Tan
Eng-King Tan
Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial [0.03%]
硫唑嘌呤治疗早期帕金森病(AZA-PD):一项随机、双盲、安慰剂对照的概念验证性二期临床试验
Julia C Greenland,Kerry Dresser,Emma Cutting et al.
Julia C Greenland et al.
Background: The immune system is implicated in Parkinson's disease aetiology and prognosis. Although there are effective symptomatic treatments for Parkinson's disease, there are currently no therapies that slow down dise...
Clinical Trial
The Lancet. Neurology. 2026 Jan;25(1):39-49. DOI:10.1016/S1474-4422(25)00386-2 2026
Tobias Kurth,Linda Al-Hassany,Christian Lampl et al.
Tobias Kurth et al.
Emmanuel Drouin,Patrick Hautecoeur,Arnaud Kwiatkowski
Emmanuel Drouin